Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03RNX
|
|||
| Former ID |
DIB001692
|
|||
| Drug Name |
EPC-K1
|
|||
| Synonyms |
CHX-3107; Phosphoric acid 2-L-ascorbyl D,L-alpha-tocopheryl diester potassium salt; 2-O-[Hydroxy[2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydro-2H-1-benzopyran-6-yloxy]phosphoryl]-L-ascorbic acid potassium salt
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Nerve injury [ICD-11: ND56.4; ICD-10: T14.4] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C35H56KO10P
|
|||
| Canonical SMILES |
CC1=C(C(=C(C2=C1OC(CC2)(C)CCCC(C)CCCC(C)CCCC(C)C)C)OP(=O)([O-])OC3=C(C(OC3=O)C(CO)O)O)C.[K+]
|
|||
| InChI |
1S/C35H57O10P.K/c1-21(2)12-9-13-22(3)14-10-15-23(4)16-11-18-35(8)19-17-27-26(7)30(24(5)25(6)31(27)43-35)44-46(40,41)45-33-29(38)32(28(37)20-36)42-34(33)39;/h21-23,28,32,36-38H,9-20H2,1-8H3,(H,40,41);/q;+1/p-1/t22-,23-,28+,32-,35-;/m1./s1
|
|||
| InChIKey |
VIHIKSJKXIMMLV-FZTHFCCHSA-M
|
|||
| CAS Number |
CAS 127061-56-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phospholipase A2 (PLA2G1B) | Target Info | Inhibitor | [2], [3] |
| BioCyc | Phospholipases | |||
| KEGG Pathway | Glycerophospholipid metabolism | |||
| Ether lipid metabolism | ||||
| Arachidonic acid metabolism | ||||
| Linoleic acid metabolism | ||||
| alpha-Linolenic acid metabolism | ||||
| Metabolic pathways | ||||
| Ras signaling pathway | ||||
| Vascular smooth muscle contraction | ||||
| Pancreatic secretion | ||||
| Fat digestion and absorption | ||||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
| Reactome | Acyl chain remodelling of PC | |||
| Acyl chain remodelling of PE | ||||
| Acyl chain remodelling of PI | ||||
| WikiPathways | Glycerophospholipid biosynthesis | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007770) | |||
| REF 2 | Posttreatment with EPC-K1, an inhibitor of lipid peroxidation and of phospholipase A2 activity, reduces functional deficits after global ischemia in rats. Brain Res Bull. 1995;36(3):257-60. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.